Program

1st day (19th March)

i day (19 iviaidi)		
8:45 -	The hall & the reception desk (at 10F lobby) opening	
9:30 -	Opening address	
	Dr. Wolfgang Weiss (ex-UNSCEAR Chair)	
	Overview of this workshop	
	Dr. Yoshiharu Yonekura (ex- NIRS President, ex-UNSCEAR Chair)	
9:45 - 11:45	Morning session	
	1.1. Dose and Dose-rate Effects	
	Chairperson: Dr. Ulrike Kulka (BfS)	
1M01	Dose- and Dose-Rate Effects of Ionizing Radiation for Cancer Incidence and	
	Life-Shortening.	
	Dr. Gayle Woloschak (Northwestern University)	
1M02	Life span and tumorigenesis in mice exposed to continuous low dose-rate	
	gamma rays.	
	Dr. Ignacia Braga-Tanaka (Institute for Environmental Sciences)	
1M03	How high can you go, radionuclide therapy is effective at low dose rate.	
	Dr. Mark Konijnenberg (Erasmus MC)	
11:45 - 13:00	Lunch break	
13:00 - 15:30	Afternoon session I	
	1.2. From Mutation to Cancer	
	Chairperson: Dr. Masako Bando (Kyoto University, Osaka University)	
1A11	Overview: The divergence of approaches from molecular biology and macro	
	level.	
	Dr. Masako Bando (Kyoto University, Osaka University)	

1A12	Responses to low dose radiation in vivo: DNA damage, aging, and immune
	regulation.
	Dr. Yi Wang (CNL)
1A13	Dose-rate effects of lymphocyte chromosome aberrations in chronically
	irradiated mice after age adjustment.
	Dr. Kimio Tanaka (Institute for Environmental Sciences)
1A14	WAM model - a dynamic equilibrium model for the dose-rate effect.
	Dr. Yuichi Tsunoyama (Kyoto University)
	Panel discussion "Overcome the divergence of approaches of molecular
	biology from macro level."
15:30 - 16:00	Coffee break
16:00 - 18:00	Afternoon session II
	1.3. Activities of the Consortium for Medicine, Chemistry and Physics at
	Osaka University
	Chairperson: Dr. Atsushi Shinohara (Osaka University)
	Opening
	Dr. Atsushi Shinohara (Graduate School of Science, Osaka Univ.)
16:05 - 16:20	Medicine and science collaborative research for targeted alpha therapy in
1A21	Osaka University.
	Dr. Koichi Fukase (Graduate School of Science, Osaka Univ.)
16:20 - 16:45	Production and isolation of At-211 for targeted alpha therapy at Osaka
1A22	University.
	Dr. Zijian Zhang (Graduate School of Science, Osaka Univ.)
16:45 - 17:10	Radiolabeling of small molecules with astatine(211At) for theranostics.
1A23	Dr. Yoshifumi Shirakami (Graduate School of Medicine, Osaka Univ.)
17:10 - 17:35	Preparation of novel anticancer drugs using At-211.
1A24	Dr. Kazuya Kabayama (Graduate School of Science, Osaka Univ.)
17:35 - 18:00	Imaging of the targeted alpha therapy for the clinical application.
1A25	Dr. Tadashi Watabe (Graduate School of Medicine, Osaka Univ.)
1A25	Dr. Tadashi Watabe (Graduate School of Medicine, Osaka Univ.)

2nd day (20th March)

9:00 - 11:30	Morning session
	2.1. Medical Database
	Chairperson: Dr. Nobuyuki Osakabe (Hitachi, Ltd.)
2M01	Biomarkers and radiation therapy for patients with head and neck cancer.
	Dr. Pierre Saintigny (Cancer Research Centre of Lyon)
2M02	Present status of patient dose in large part of the world.
	Dr. Madan Rehani (MGH, HMS/IAEA)
2M03	Millennial medical record project - Toward establishment of authentic
	Japanese version EHR and secondary use of medical data –
	Dr. Hiroyuki Yoshihara (Kyoto University, University of Miyazaki)
	Panel discussion "How can medical database be effectively used in the BER study and practice?"
	Panelist: Dr. Nobuyuki Osakabe (Hitachi, Ltd.) & all speakers
11:30 - 13:00	Lunch break
13:00 - 15:00	Afternoon session I
	2.2. Imaging Techniques for Radiotherapy and Cancer diagnosis
	(Big data and diagnosis, treatment)
	Chairperson: Dr. Jun'ichi Kotoku (Teikyo University)
2A11	Potentials of Radiomics in Cancer Treatment.
	Dr. Hidetaka Arimura (Kyushu University)
2A12	Imaging database and radiomics.
	Dr. Akihiro Haga (Tokushima University)
2A13	Radiomics on MRI field.
	Dr. Koji Sakai (Kyoto Prefectural University of Medicine)

15:00 - 15:30	Coffee break
15:30 - 17:30	Afternoon session II
	2.3. Radiation Biology and Medical Use
	Chairperson: Dr. Akihiro Haga (Tokushima University)
2A21	Contribution of biological analysis platform to optimize the medical use of
	ionizing radiation.
	Dr. Ulrike Kulka (BfS)
2A22	Quantitative personalized oncology - Mathematical models for precision
	radiotherapy.
	Dr. Heiko Enderling (Moffitt Cancer Center)
2A23	Medical radiation protection research strategies in Europe and the role of the
	medical physicist in Europe.
	Dr. Christoph Hoeschen (Otto-von-Guericke University)
18:00 - 19:30	Poster session Room No.406 (4F)
19:30 - 21:30	Reception (Welcome meeting) Salon (9F)

3rd day (21st March)

9:00 - 11:30	Morning Session
	3.1. Presidential Session: International Cooperation in Biological Effects
	of Radiation
	Chairperson: Dr. Yoshiharu Yonekura (ex-UNSCEAR Chair)
3M01	Understanding low dose radiation exposure effects : MELODI's views on
	developing international cooperation.
	Dr. Jacques Repussard (MELODI)
3M02	Electric Power Research Institute International Dose Effect Alliance.
	Dr. Donald A. Cool (EPRI, IDEA)
3M03	Low-Dose Radiobiology Program at Canadian Nuclear Laboratories: Past,
	Present and Future.
	Dr. Dmitry Klokov (CNL)
3M04	Planning and Acting Network for Low Dose Radiation Research (PLANET) and
	promotion for integrated network in Japan.
	Dr. Yutaka Yamada / Dr. Yoshiya Shimada (QST, PLANET)
3M05	JSPS committee "multidisciplinary research on the biological effects of
	radiation".
	Dr. Takahiro Wada (JSPS committee)
	Short talks on each organization / panel discussions
11:30 - 13:00	Lunch break
13:00 - 15:00	Afternoon session I
	3.2. Radiation Protection in Medicine
	3.2.1. Radiation induced cancer
	Chairperson: Dr. Yoshiya Shimada (QST)

3A11	Radiation protection in therapy with radiopharmaceuticals.
	Dr. Makoto Hosono (Kindai University)
3A12	Experimental evaluation of the carcinogenic effect of carbon ions and neutrons
	in children.
	Dr. Tatsuhiko Imaoka (NIRS, QST)
3A13	Second cancer after radiotherapy.
	Dr. Jean-Marc Cosset (Amethyst Group, former ICRP C3 member)
15:00 - 15:30	Coffee break
15:30 - 17:30	Afternoon session II
	3.2.2. New medical equipment for less radiation dose
	Chairperson: Dr. Makoto Hosono (Kindai University)
3A21	Cancer risk from paediatric CT scanning.
	Dr. Elisabeth Cardis (Institut de Salut Global de Barcelona)
3A22	Low-dose CT screening for lung cancer.
	Dr. Takeshi Nawa (Hitachi General Hospital)
3A23	Development of low dose diagnostic CT.
	Dr. Takashi Tanaka (Canon Medical Systems)
17:30 - 17:45	Closing Remarks